Necessary

Neurotoxicity is the adverse reaction of compounds to the structure and function of the nervous system, which may cause long-term or even permanent damage to the nervous system, especially to the developing central nervous system. Neurotoxicity has the characteristics of concealed toxicity, significant harm, and irreversibility in drug evaluation. It is not only an important reason for the failure of many projects in clinical research, but also one of the reasons for the withdrawal of marketed drugs from the market. Therefore, neurotoxicity testing needs to be emphasized in non-clinical safety evaluation of drugs.

ICE is committed to providing customers with high-quality and comprehensive drug screening and evaluation services, establishing models of neural cell lines and primary neural cells as a tool for early screening of neurotoxic drugs, providing toxicity evidence support for subsequent clinical trials, and reducing drug development risks. We have also established a high content screening (HCS) imaging platform, which uses computer software to quantitatively analyze cell specific components of different fluorescent markers. Multi parameter determination can comprehensively evaluate the morphological characteristics of nerve cells, conduct high-throughput screening and evaluation, and accelerate the process of drug development.

Model:

Primary rat and mouse neural cells (cortex, hippocampus, dorsal root ganglion), HT22, PC12, and sh-SY5Y cell lines (differentiated and undifferentiated)

Detection methods and indicators:

Cell viability detection: CTG, CCK-8, LDH, PI/Hoechst

Mitochondrial damage detection: mitochondrial membrane potential (JC-1), mitochondrial ROS (Mito ROS), mitochondrial calcium homeostasis (Rhod-2-AM)

Detection of intracellular oxidative damage: intracellular ROS (H2DCFDA)

Neurite growth: neurite length and Sholl analysis (MAP-2)

Electrophysiology: patch clamp, MEA